Crohn's Disease Market Report 2034: Epidemiology Insights, Pipeline Developments, and Key Regulatory Approvals (FDA, EMA, PMDA) | Published by DelveInsight | Featuring Leading Companies: Takeda Pharma

Crohn's Disease companies are Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others.
DelveInsight's "Crohn's Disease Market Insights, Epidemiology, and Market Forecast-2034" provides a comprehensive analysis of Crohn's Disease, covering historical and projected epidemiological trends along with current and future market dynamics in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Crohn's Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Crohn's Disease Market Forecast [https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Some of the key facts of the Crohn's Disease Market Report:

*
The Crohn's Disease treatment market in the seven major markets (7MM) was valued at approximately USD 9 billion in 2023 and is expected to experience substantial growth by 2034.

*
In December 2024, Celltrion received FDA approval for STEQEYMA Registered (ustekinumab-stba), a biosimilar of STELARA Registered (ustekinumab), for subcutaneous or intravenous use in adult and pediatric patients with plaque psoriasis, psoriatic arthritis, and adult patients with Crohn's disease and ulcerative colitis. Similarly, on October 14, 2024, Dong-A-ST announced that its biosimilar Imuldosa (ustekinumab-srlf/DMB-3115) was FDA-approved for autoimmune conditions, including plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, offering a more cost-effective alternative to the original drug, Stelara, which had global sales of $10.86 billion in 2023.

*
Also in October 2024, Eli Lilly reported that mirikizumab showed superior histologic response compared with ustekinumab at Week 52 in patients with moderately to severely active Crohn's disease, regardless of prior biologic therapy. These results from the VIVID-1 Phase 3 trial, based on systematic bowel segment assessment following ECCO guidelines, were presented at UEG Week in Vienna.

*
During the same period, Johnson & Johnson presented positive Phase 3 data for TREMFYA Registered (guselkumab) in Crohn's disease and ulcerative colitis. Results from the GALAXI 2 & 3 and QUASAR maintenance studies showed high endoscopic remission rates in both biologic-naive and biologic-refractory patients, including those unresponsive to JAK inhibitors, demonstrating TREMFYA's potential as an effective option for difficult-to-treat cases.

*
Crohn's disease, a type of Inflammatory Bowel Disease (IBD), causes digestive tract inflammation, leading to symptoms like abdominal pain, diarrhea, fatigue, weight loss, and malnutrition. It can affect different parts of the digestive system and is often diagnosed in individuals aged 20-30. Crohn's disease subtypes include ileocolitis, ileitis, gastroduodenal CD, jejunoileitis, and Crohn's colitis. The exact cause remains unclear, though genetic factors, immune dysfunction, and environmental influences are thought to contribute. Symptoms can range from mild to severe, sometimes affecting areas outside the gastrointestinal tract, and may include abdominal cramps, fever, anemia, and perianal fistulas.

*
Diagnosis involves clinical evaluation, imaging, endoscopy, and pathological studies to rule out other conditions like ulcerative colitis or cancer, with blood tests used to monitor disease activity. In 2023, approximately 1.97 million diagnosed cases were reported in the 7MM, with numbers expected to rise. Initial treatment includes aminosalicylates, antibiotics, and corticosteroids, while immunomodulators are used for maintenance. Among treatment classes, Anti-TNF therapies generated the highest revenue in 2023, followed by Anti-integrin therapies.

*
Despite treatment advances, challenges such as long-term side effects, high costs, and adherence issues highlight the need for novel therapies. World IBD Day, observed annually on May 19, raises awareness for Crohn's disease and ulcerative colitis, supporting the 10 million people worldwide living with IBD.

*
Leading companies shaping the Crohn's disease market include Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others.

*
Country-wise and therapy-wise insights:

*
In 2023, the U.S. market was approximately USD 7.3 billion, projected to grow at a CAGR of ~5% through 2034.

*
Among 7MM countries, Spain had the smallest market share (~2%).

*
In the EU4+UK, Germany held the largest share (~35%).

*
Adalimumab led the market in 2023, generating around USD 3.4 billion across the 7MM.

*
In the U.S., about 430,000 mild cases and 640,000 moderate-to-severe cases were treated with first-line therapies in 2023.

*
Key therapies: ENTYVIO (Vedolizumab), STELARA (Ustekinumab), VELSIPITY (etrasimod), Zeposia (Ozanimod; RPC1063), and others.

*
The Crohn's Disease market is expected to expand significantly due to increasing disease prevalence and awareness, with the introduction of multiple-stage pipeline products anticipated to transform market dynamics in the coming years.

Crohn's Disease Overview

Crohn's disease is a long-term inflammatory bowel disease (IBD) characterized by inflammation throughout the digestive tract. While it can involve any part of the gastrointestinal (GI) system, it most frequently affects the ileum (the final section of the small intestine) and the colon.

Get a Free sample for the Crohn's Disease Market Forecast [https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr], Size & Share Analysis Report

Crohn's Disease Epidemiology

The epidemiology section offers a detailed overview of past, present, and projected trends in the seven major markets (7MM) from 2020 to 2034. It examines the underlying factors driving these trends by analyzing findings from multiple studies and insights from key opinion leaders. Additionally, the section provides a comprehensive assessment of the diagnosed patient population and highlights anticipated developments in the future.

Crohn's Disease Epidemiology Segmentation:

The Crohn's Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Diagnosed Prevalence of Crohn's Disease in Adults

*
Diagnosed Prevalence of Crohn's Disease in Pediatrics

*
Diagnosed Prevalence of Crohn's Disease by Types

*
Diagnosed Prevalence of Crohn's Disease by Location

*
Diagnosed Prevalence of Crohn's Disease by Severity

Download the report to understand which factors are driving Crohn's Disease epidemiology trends [https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Crohn's Disease Marketed Drugs

*
ENTYVIO (Vedolizumab): Takeda Pharmaceutical

*
STELARA (Ustekinumab): Janssen Pharmaceuticals

Crohn's Disease Emerging Drugs

*
VELSIPITY (etrasimod): Pfizer/Arena Pharmaceuticals

*
Zeposia (Ozanimod; RPC1063): Celgene (Bristol Myers Squibb)

Crohn's Disease Therapies: ENTYVIO (Vedolizumab), STELARA (Ustekinumab), VELSIPITY (etrasimod), Zeposia (Ozanimod; RPC1063), and others

Crohn's Disease Key Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others

Discover more about therapies set to grab major Crohn's Disease market share @ Crohn's Disease Treatment Landscape [https://www.delveinsight.com/sample-request/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Crohn's Disease Market Outlook

Crohn's disease is a type of inflammatory bowel disease (IBD), a group of disorders marked by chronic intestinal inflammation, leading to pain and swelling. If inadequately treated, the disease can progress, causing long-term damage to the intestinal lining and recurring flare-ups with acute symptoms. Management strategies include nutritional therapy, smoking cessation, and medications, while surgery may be necessary in severe or refractory cases. The primary aims of pharmacological treatment are to relieve symptoms, improve or maintain quality of life, and minimize side effects.

Currently, the biologics segment for Crohn's disease is dominated by anti-TNF agents such as adalimumab and infliximab. However, newer drug classes, including anti-integrins and interleukin inhibitors, are gaining popularity due to favorable safety profiles (e.g., no black box warnings) and convenient dosing schedules. Patients not achieving remission with conventional therapies may escalate to advanced biologics, including infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, and ustekinumab. Surgery is considered when medications fail to control the disease or address complications.

The Crohn's disease drug market is expected to expand, driven by the launch of innovative therapies with improved efficacy and administration methods, increased use of targeted treatments, ongoing research and development, discovery of new diagnostic biomarkers, and a rising disease prevalence. Market growth may, however, be tempered by the entry of biosimilars, delays in accurate diagnosis, and the challenges of managing complex cases such as fistulizing Crohn's disease.

Scope of the Crohn's Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Crohn's Disease Companies: Takeda Pharmaceutical, Janssen Pharmaceuticals, UCB, Biogen, AbbVie, AstraZeneca, Tillotts Pharma (Zeria Pharmaceutical), Gilead Sciences and Galapagos NV, Boehringer Ingelheim, Celgene (Bristol Myers Squibb), Eli Lilly and Company, RedHill Biopharma, Arena Pharmaceuticals, Mesoblast, and others

*
Key Crohn's Disease Therapies: ENTYVIO (Vedolizumab), STELARA (Ustekinumab), VELSIPITY (etrasimod), Zeposia (Ozanimod; RPC1063), and others

*
Crohn's Disease Therapeutic Assessment: Crohn's Disease current marketed and Crohn's Disease emerging therapies

*
Crohn's Disease Market Dynamics: Crohn's Disease market drivers and Crohn's Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Crohn's Disease Unmet Needs, KOL's views, Analyst's views, Crohn's Disease Market Access and Reimbursement

To know more about Crohn's Disease companies working in the treatment market, visit @ Crohn's Disease Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/report-store/crohns-disease-cd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Crohn's Disease Market Report Introduction

2. Executive Summary for Crohn's Disease

3. SWOT analysis of Crohn's Disease

4. Crohn's Disease Patient Share (%) Overview at a Glance

5. Crohn's Disease Market Overview at a Glance

6. Crohn's Disease Disease Background and Overview

7. Crohn's Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Crohn's Disease

9. Crohn's Disease Current Treatment and Medical Practices

10. Crohn's Disease Unmet Needs

11. Crohn's Disease Emerging Therapies

12. Crohn's Disease Market Outlook

13. Country-Wise Crohn's Disease Market Analysis (2020-2034)

14. Crohn's Disease Market Access and Reimbursement of Therapies

15. Crohn's Disease Market Drivers

16. Crohn's Disease Market Barriers

17. Crohn's Disease Appendix

18. Crohn's Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Crohn's Disease Pipeline

"Crohn's Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Crohn's Disease market. A detailed picture of the Crohn's Disease pipeline landscape is provided, which includes the disease overview and Crohn's Disease treatment guidelines.

Crohn's Disease Epidemiology

DelveInsight's 'Crohn's Disease Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Crohn's Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=crohns-disease-market-report-2034-epidemiology-insights-pipeline-developments-and-key-regulatory-approvals-fda-ema-pmda-published-by-delveinsight-featuring-leading-companies-takeda-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.